Revascularization and cardioprotective drug treatment in myocardial infarction patients: How do they impact on patients' survival when delivered as usual care

Alain Vanasse, Josiane Courteau, Théophile Niyonsenga

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
29 Downloads (Pure)


Background: Randomized clinical trials showed the benefit of pharmacological and revascularization treatments in secondary prevention of myocardial infarction (MI), in selected population with highly controlled interventions. The objective of this study is to measure these treatments' impact on the cardiovascular (CV) mortality rate among patients receiving usual care in the province of Quebec. Methods: The study population consisted of a "naturalistic" cohort of all patients ≥ 65 years old living in the Quebec province, who survived a MI (ICD-9: 410) in 1998. The studied dependant variable was time to death from a CV disease. Independent variables were revascularization procedure and cardioprotective drugs. Death from a non CV disease was also studied for comparison. Revascularization procedure was defined as percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG). The exposure to cardioprotective drugs was defined as the number of cardioprotective drug classes (Acetylsalicylic Acid (ASA), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Statins) claimed within the index period (first 30 days after the index hospitalization). Age, gender and a comorbidity index were used as covariates. Kaplan-Meier survival curves, Cox proportional hazard models, logistic regressions and regression trees were used. Results: The study population totaled 5596 patients (3206 men; 2390 women). We observed 1128 deaths (20%.) within two years following index hospitalization, of them 603 from CV disease. The CV survival rate at two years is much greater for patients with revascularization, regardless of pharmacological treatments. For patients without revascularization, the CV survival rate increases with the number of cardioprotective drug classes claimed. Finally, Cox proportional hazard models, regression tree and logistic regression analyses all revealed that the absence of revascularization and, to a lower extent, absence of cardioprotective drugs were major predictors for CV death, even after adjusting for age, gender and comorbidity. Conclusion: Considering usual care management of MI in the province of Quebec in 1998, CV survival is positively correlated to the presence of a revascularization procedure and to the intensity of cardioprotective pharmacological treatment. These results are coherent with data from randomized control trials.

Original languageEnglish
Article number21
Pages (from-to)1-9
Number of pages9
JournalBMC Cardiovascular Disorders
Publication statusPublished - 2006
Externally publishedYes


Dive into the research topics of 'Revascularization and cardioprotective drug treatment in myocardial infarction patients: How do they impact on patients' survival when delivered as usual care'. Together they form a unique fingerprint.

Cite this